Format

Send to

Choose Destination
Ann N Y Acad Sci. 2003 Mar;983:208-12.

Promoter hypermethylation as an epigenetic component in Type I and Type II endometrial cancers.

Author information

1
Laboratory of Biosystems and Cancer, National Cancer Institute, Bethesda, Maryland 20892, USA.

Abstract

Epigenetic mechanisms that result in aberrant gene expression are a prominent feature of many cancer types. One main epigenetic mechanism for gene silencing involves promoter hypermethylation. Type I and type II endometrial cancers exhibit differing clinical, histologic, and molecular genetic characteristics. We hypothesize that these differences also extend to epigenetic phenomena. Promoter methylation analysis of 11 genes in a panel of endometrial cancers supports this hypothesis. These initial data indicate that promoter hypermethylation events occur frequently in type 1 cancer and were not detected in type II cancers using this panel of loci. These data tend to support the hypothesis that type I and type II endometrial cancers will exhibit distinct patterns of gene silencing based on promoter hypermethylation events.

PMID:
12724225
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Wiley
Loading ...
Support Center